JAZZ Q3 2019 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$538M+14.6% YoY

Gross Profit

$506M94.2% margin

Operating Income

$133M24.8% margin

Net Income

$102M19.0% margin

EPS (Diluted)

$1.78

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

$338M

Free Cash Flow

$268M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$5.5B

Total Liabilities

$2.5B

Stockholders' Equity

$3.1B

Cash & Equivalents

$795M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$538M	$469M	+14.6%
Gross Profit	$506M	$443M	+14.3%
Operating Income	$133M	$189M	-29.5%
Net Income	$102M	$149M	-31.5%

Revenue Segments

Product And Services, Product Sales

$532M50%

Xyrem

$426M40%

Defitelio/Defibrotide

$38M4%

Erwinaze And Erwinase

$34M3%

Vyxeos

$30M3%

Product And Services, Royalties And Contract Revenue

$5M1%

Other Products

$4M0%

Sunosi

$987,0000%

Geographic Segments

UNITED STATES

$492M92%

Europe

$35M7%

Other Countries

$10M2%